Axsome Therapeutics (AXSM) Other financing activities (2022 - 2026)

Axsome Therapeutics' Other financing activities history runs 5 years deep, the most recent figure standing at $95000.0 for Q1 2026.

• In Q1 2026, Other financing activities fell 75.83% year-over-year to $95000.0; the TTM figure through Mar 2026 stood at $899000.0 (down 25.64% YoY), while the FY2025 annual figure was $1.2 million, up 46.69% from the prior year.
• Other financing activities came in at $95000.0 for Q1 2026 at Axsome Therapeutics, up from -$2.4 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $12.4 million in Q2 2023 to a low of -$2.4 million in Q4 2025.
• A 5-year average of $2.0 million and a median of $455000.0 in 2025 frame the typical range for Other financing activities.
• On a YoY basis, Other financing activities climbed as much as 941.22% in 2025 and fell as far as 841.95% in 2025.
• Axsome Therapeutics' Other financing activities stood at $6.5 million in 2022, then sank by 68.46% to $2.0 million in 2023, then sank by 83.92% to $329000.0 in 2024, then slumped by 841.95% to -$2.4 million in 2025, then soared by 103.89% to $95000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $95000.0, -$2.4 million, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison